Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SL Science HoldingSLBT +24.39%12 EBITDA Margin % is -200.37% as of Dec. 2025. GuruFocus rates SLBT with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 942 Biotechnology companies, SL Science Holding ranks worse than 59.55% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. SL Science Holding's EBITDA for the
six
months ended in Dec. 2025 was $-2.14 Mil. SL Science Holding's Revenue for the
six
months ended in Dec. 2025 was $1.07 Mil. Therefore, SL Science Holding's EBITDA margin for the quarter that ended in Dec. 2025 was -200.37%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
SL Science Holding EBITDA Margin % Related Terms
SL Science Holding EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for SL Science Holding's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SL Science Holding EBITDA Margin % Chart
SL Science Holding Annual Data
Trend
Dec23
Dec24
Dec25
EBITDA Margin %
15.24
-34.16
-170.41
SL Science Holding Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
EBITDA Margin %
0.00
-38.59
-31.62
-142.07
-200.37
SLBT vs DMRA, BCAX, TYRA: EBITDA Margin % Comparison
For the Biotechnology subindustry, SL Science Holding's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SL Science Holding EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SL Science Holding's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where SL Science Holding's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SL Science Holding (SLBT) has a EBITDA Margin % of -200.37% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SL Science Holding and its competitors. According to the industry distribution chart, SL Science Holding ranks #561 out of 942 companies in the Biotechnology industry, placing it in the top 59.6%.
Is SL Science Holding's EBITDA Margin % too high?
SL Science Holding's current EBITDA Margin % is -200.37%. Based on the distribution chart, SL Science Holding ranks #561 out of 942 companies in the Biotechnology industry, which is below the industry midpoint. Overall, SL Science Holding has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SL Science Holding's EBITDA Margin % compare to DMRA and BCAX?
According to the Biotechnology industry distribution chart, SL Science Holding ranks #561 out of 942 companies for EBITDA Margin %. This places SL Science Holding in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SL Science Holding and its competitors. SL Science Holding's current EBITDA Margin % is -200.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SL Science Holding stock overvalued right now?
SL Science Holding (SLBT) has a current EBITDA Margin % of -200.37%. The current EBITDA Margin % is -200.37%. SL Science Holding's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For SL Science Holding (SLBT), the current EBITDA Margin % is -200.37% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
12GF Score
Get the complete analysis for SLBT
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLBT has been successfully added to your 
